B. Metzler seel. Sohn & Co. AG raised its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 17.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 131,477 shares of the company's stock after purchasing an additional 19,693 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Kenvue were worth $2,807,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Skba Capital Management LLC boosted its position in shares of Kenvue by 6.4% during the 4th quarter. Skba Capital Management LLC now owns 601,330 shares of the company's stock valued at $12,838,000 after acquiring an additional 36,070 shares in the last quarter. O Shaughnessy Asset Management LLC grew its stake in shares of Kenvue by 28.4% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 59,771 shares of the company's stock valued at $1,276,000 after purchasing an additional 13,203 shares during the period. Schroder Investment Management Group grew its position in Kenvue by 0.6% in the fourth quarter. Schroder Investment Management Group now owns 160,305 shares of the company's stock valued at $3,395,000 after acquiring an additional 950 shares during the period. Allstate Corp bought a new stake in Kenvue during the 4th quarter worth approximately $1,228,000. Finally, DnB Asset Management AS raised its position in Kenvue by 6.3% in the 4th quarter. DnB Asset Management AS now owns 381,232 shares of the company's stock valued at $8,139,000 after purchasing an additional 22,590 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Citigroup reduced their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and reduced their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $24.00.
Read Our Latest Stock Report on KVUE
Kenvue Stock Down 5.5 %
Shares of KVUE stock traded down $1.29 during trading on Friday, reaching $22.33. The company's stock had a trading volume of 17,763,957 shares, compared to its average volume of 16,812,043. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The business has a fifty day moving average price of $22.59 and a 200-day moving average price of $22.46. The company has a market cap of $42.68 billion, a price-to-earnings ratio of 42.14, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
